Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects

ClinicalTrials.gov · COMPLETED, 2020

23 participants

Abstract

The aim of the study is to provide insight into the impact of the immunosuppressant drug sirolimus, on the antidepressant effects of the prototypal rapid-acting antidepressant medication, ketamine.

Conditions: Depression.

Primary outcome: Montgomery-Asberg Depression Rating Scale.

Enrollment: 23 participants.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 23 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

• ClinicalTrials.gov
• Publisher page

Related studies

• Diarylethenes for Memories and Switches Chemical Reviews, 2000
• Long-Term Potentiation and Memory Physiological Reviews, 2004
• Social Memory Studies: From “Collective Memory” to the Historical Sociology of Mnemonic Practices Annual Review of Sociology, 1998
• The Cognitive Neuroscience of Working Memory Annual Review of Psychology, 2014
• Memory aging and brain maintenance Trends in Cognitive Sciences, 2012
• Effector and Memory CTL Differentiation Annual Review of Immunology, 2006

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free